Pharmaceuticals, Biotechnology and Life Sciences
Leading biopharmaceutical organizations join Project Baseline initiative to engage more patients and clinicians in research and speed evidence generation SAN…
Sandoz is resubmitting its Biologics License Application for a proposed biosimilar pegfilgrastim to the US FDA
Novartis got approval from the China Health Authority NMPA for
Cosentyx, its the first-in-class interleukin-17A inhibitor for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
Novartis has purchased a subsidiary of IFM Therapeutics LLC focused on developing ani-inflammatory medicines targeting the NLRP3 inflammasome, which will add one clinical and two preclinical programs targeting the NLRP3 inflammasome, a key component of the innate immune system.
Novartis on Wednesday said that it got approval from the FDA for Mayzent for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease, in adults.
Novartis’ eye care division Alcon has bought a privately-held US medical device company PowerVision, which focuses on focused on creating fluid-based intraocular lens implants, for $285 million at closing with additional payments based on specified regulatory and commercial milestones starting in 2023.
Novartis has had Cosentyx compared against Janssen’s IL-23 Stelara, and it showed superior improvements for psoriasis patients, it said in a statement Tuesday, noting that it was processed and transmitted by West Corporation.
Novartis will exercise its option for worldwide responsibility of TQJ230, an investigational agent for targeted cardiovascular therapy previously known as AKCEA-APO(a)-LRx, from Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals.
Beximco Pharmaceuticals Limited will buy from Novartis’ Sandoz a portfolio of eight Abbreviated New Drug Applications (ANDAs) in the US…
Patients with certain plaque psoriasis treated with 300mg of Cosentyx for only four weeks reported in a questionnaire improvements in life quality, novartis said Monday.